Prosecution, oppositions, nullity proceedings and litigation (patent infringement, compulsory licences) in the field of pharmaceutical and biotech IP on ibandronate, neutrokine-alpha (BLys), HSA, BGH, insulin, interferons, interleukins, G-CSF, GM-CSF, EPO, tPA, BRCA1 and BRCA2, p10, recombinant viruses, vaccines (viral, bacterial), HPV diagnostics, gene therapy, production of recombinant plants, transgenic animals, stem cells, bacterial, yeast and mammalian expression systems, humanized glycosylation in yeasts, purification of recombinantly produced proteins, antibody technology (monoclonals, single chain, single variable domain, humanized antibody design, anti-PD1-antibodies, anti-CD27-antibodies,
trastuzumab, rituximab, golimumab, belimumab, brentuximab, ranibizumab, diabodies), PCR, Taq Man PCR, Taq polymerase, Enzyme replacement therapies, NASBA, LCR, antisense technology, ribozymes, RNAi, CRISPR, functional genomics.
PhD in molecular biology, 1984; German Patent Attorney, 1987; European Patent Attorney, 1988; European Trademark Attorney, 1995.
Member of the German Patent Attorney Bar Association, EPI, FICPI, AIPPI, GRUR.
Numerous lectures and articles about patenting biotech inventions in the EPO and the GPTO and about enforcing such patents. Publication of 'From Clones to Claims', Carl Heymanns Verlag, sixth edition, 2015, on biotech case law by the EPO, co-authored by Jürgen Meier, Leslie McDonell, James F Haley Jr and Yoshinori Hosoda.